Cargando…

Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results

The traditional treatment of venous thromboembolism (VTE) has been use of heparin and vitamin K antagonists (VKA), and although shown to be effective, they have numerous limitations. New oral anticoagulants (NOACs) including direct thrombin (factor IIa) inhibitors (dabigatran) and selective factor X...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Alexander T., Imfeld, Stephan, Rider, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033807/ https://www.ncbi.nlm.nih.gov/pubmed/24821599 http://dx.doi.org/10.1007/s12325-014-0119-7

Ejemplares similares

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
por: Burnett, Allison E., et al.
Publicado: (2016)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Menstruation, anticoagulation, and contraception: VTE and uterine bleeding
por: Samuelson Bannow, Bethany, et al.
Publicado: (2021)

Extended anticoagulation for VTE: what evidence justifies it?
por: Walia, Anushka, et al.
Publicado: (2023)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

Duration of anticoagulant therapy and VTE recurrence in patients with cancer
por: Khorana, Alok A., et al.
Publicado: (2019)

Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE
por: Xiong, Wei, et al.
Publicado: (2023)

Commentary and Critique to “VTE Prophylaxis Therapy: Clinical Practice vs Clinical Guidelines” by Abukhalil et al [Letter]
por: Güven, Alper Tuna, et al.
Publicado: (2022)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

A critique of Karl Popper's methodology
por: Johansson, Ingvar
Publicado: (1975)

Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants
por: Luger, Sebastian, et al.
Publicado: (2015)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Response to Commentary and Critique to “VTE Prophylaxis Therapy: Clinical Practice vs Clinical Guidelines” by Abukhalil et al [Response to Letter]
por: Abukhalil, Abdallah Damin
Publicado: (2022)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
por: Amin, A., et al.
Publicado: (2009)

Trial Protocol: A randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study)
por: Tullett, Jayne, et al.
Publicado: (2013)

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
por: Woodruff, Seth, et al.
Publicado: (2016)

Reviews of Functional MRI: The Ethical Dimensions of Methodological Critique
por: Anderson, James, et al.
Publicado: (2012)

Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes
por: Benavente, Lorena, et al.
Publicado: (2010)

What’s new in VTE risk and prevention in orthopedic surgery
por: Kahn, Susan R., et al.
Publicado: (2020)

Antithrombin III levels in critically ill surgical patients: do they correlate with VTE?
por: Bhatti, Umar F, et al.
Publicado: (2023)

Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial.
por: Bradbury, Charlotte, et al.
Publicado: (2019)

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
por: Khorana, Alok A., et al.
Publicado: (2018)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Review of Therapeutic Options for the Prevention of VTE in Total Joint Arthroplasty
por: Etscheidt, Jordan, et al.
Publicado: (2020)

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis
por: Rasmussen, Lars Hvilsted, et al.
Publicado: (2012)

Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials
por: Ayabe, Kengo, et al.
Publicado: (2016)

Psychotropic Polypharmacy in the US Pediatric Population: A Methodologic Critique and Commentary
por: Zito, Julie M., et al.
Publicado: (2021)

VTE risk assessment in pregnancy
por: Ewins, Karl, et al.
Publicado: (2019)

Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation
por: Park, Jiesuck, et al.
Publicado: (2019)

Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?
por: Frere, Corinne, et al.
Publicado: (2020)

Preventing VTE following total hip and knee arthroplasty: Is prediction the future?
por: Nemeth, Banne, et al.
Publicado: (2020)

Sickle Cell Trait: Is There an Increased VTE Risk in Pregnancy and the Postpartum?
por: Pintova, Sofya, et al.
Publicado: (2013)

The management of acute venous thromboembolism in clinical practice: Results from the European PREFER in VTE Registry
por: Cohen, Alexander T., et al.
Publicado: (2017)

Critique
Publicado: (1953)

The Critique
Publicado: (1898)

Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation
por: Paquette, Miney, et al.
Publicado: (2020)

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2016)

Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis
por: van Hout, Ben, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0bf7erctb1kolrmi8c8uedgiig